Comparing Azurrx Biopharm (AZRX) and Teva Pharmaceutical Industries Limited (TEVA)
Azurrx Biopharm (NASDAQ: AZRX) and Teva Pharmaceutical Industries Limited (NYSE:TEVA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.
This is a summary of recent recommendations and price targets for Azurrx Biopharm and Teva Pharmaceutical Industries Limited, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Teva Pharmaceutical Industries Limited||5||16||6||0||2.04|
Azurrx Biopharm currently has a consensus target price of $7.50, indicating a potential upside of 152.53%. Teva Pharmaceutical Industries Limited has a consensus target price of $22.97, indicating a potential upside of 96.82%. Given Azurrx Biopharm’s stronger consensus rating and higher probable upside, analysts plainly believe Azurrx Biopharm is more favorable than Teva Pharmaceutical Industries Limited.
Earnings and Valuation
This table compares Azurrx Biopharm and Teva Pharmaceutical Industries Limited’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Azurrx Biopharm||N/A||N/A||-$14.59 million||N/A||N/A|
|Teva Pharmaceutical Industries Limited||$21.90 billion||0.54||$329.00 million||($5.95)||-1.96|
Teva Pharmaceutical Industries Limited has higher revenue and earnings than Azurrx Biopharm.
This table compares Azurrx Biopharm and Teva Pharmaceutical Industries Limited’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Teva Pharmaceutical Industries Limited||-24.35%||15.70%||5.12%|
Institutional and Insider Ownership
6.1% of Azurrx Biopharm shares are held by institutional investors. Comparatively, 56.5% of Teva Pharmaceutical Industries Limited shares are held by institutional investors. 9.1% of Azurrx Biopharm shares are held by company insiders. Comparatively, 7.1% of Teva Pharmaceutical Industries Limited shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Teva Pharmaceutical Industries Limited pays an annual dividend of $0.94 per share and has a dividend yield of 8.1%. Azurrx Biopharm does not pay a dividend. Teva Pharmaceutical Industries Limited pays out -15.8% of its earnings in the form of a dividend.
Teva Pharmaceutical Industries Limited beats Azurrx Biopharm on 8 of the 12 factors compared between the two stocks.
About Azurrx Biopharm
AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women’s health and selected other areas.
Receive News & Ratings for Azurrx Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azurrx Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.